Piper Sandler analyst David Westenberg lowered the firm’s price target on Myriad Genetics (MYGN) to $14 from $24 and keeps a Neutral rating on ...

The study found that Prequel ® Prenatal Screen with AMPLIFY™ technology enables reliable results as early as eight-weeks’ gestation. Typically, prenatal cell-free DNA (pcfDNA) screening is offered ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 3.75% of ...

Myriad Genetics, Inc. is headquartered in Salt Lake City, UT. The company is focused on developing, producing and distributing genetic tests utilized in the oncology and women's and ...

Los Angeles, California--(Newsfile Corp. - January 16, 2025) - OG DNA Genetics Inc. (the "Corporation") announced today the results of its substantial issuer bid (as varied and extended on ...

Shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) have received a consensus rating of “Hold” from the twelve brokerages that are presently covering the stock, MarketBeat reports.

SAN FRANCISCO — At the JP Morgan Healthcare Conference here on Wednesday, Myriad Genetics CEO Paul Diaz provided preliminary Q4 and full-year 2024 financial results, as well as full-year 2025 guidance ...

A common antihistamine may offer hope for patients with a rare genetic disease that can lead to severe liver damage and ultimately require transplantation, according to new research from Rutgers ...

These preliminary results will be included in a presentation that will be made available through a live webcast in the investor relations section of the Myriad Genetics website at investor.myriad.com ...

Cemex S.A.B. de C.V. Series A 0.00% $57.52B Cemex S.A.B. de C.V. Series B 0.00% ...

These preliminary results will be included in a presentation that will be made available through a live webcast in the investor relations section of the Myriad Genetics website at investor.myriad ...